efalizumab
Sign in to saveAlso known as Anti-Cd11A, hu1124, antiCD11 alpha, anti alphaL integrin
Efalizumab (brand name Raptiva) is a formerly available medication designed to treat autoimmune diseases, originally marketed to treat psoriasis. It is a recombinant humanized monoclonal antibody administered once weekly by subcutaneous injection. Efalizumab binds to the CD11a subunit of lymphocyte function-associated antigen 1 and acts as an immunosuppressant by inhibiting lymphocyte activation and cell migration out of blood vessels into tissues. Efalizumab was associated with fatal brain infections and was withdrawn from the market in 2009.
In the Vinony graph
Within Vinony's link graph, efalizumab is referenced by 277 other articles, and connects out to medication, monoclonal antibody and immunosuppressive drug.
Vinony files it under Chemicals that do not have a ChemSpider ID assigned, Drugboxes which contain changes to verified fields and Drugs developed by Genentech.
Its subject is documented across 14 Wikipedia language editions.
Key facts
- Drug.Verifiedfields
- changed
- Drug.verifiedrevid
- 461092863
- Drug.type
- mab
- Drug.mab_type
- mab
- Drug.source
- zu/o
- Drug.target
- CD11a
- Drug.tradename
- Raptiva
- Drug.routes_of_administration
- Subcutaneous
- Drug.ATC_prefix
- L04
- Drug.ATC_suffix
- AG02
- Drug.CAS_number
- 214745-43-4
- Drug.DrugBank
- DB00095
- Drug.ChemSpiderID
- none
- Drug.UNII
- XX2MN88N5D
- Drug.ChEMBL
- 1201575
- Drug.melting_point
- 66
via Wikipedia infobox
Chemical data
Drug data · ChEMBL
Withdrawn- Max clinical phase
- Approved
- Molecule type
- Antibody
- First approval
- 2003
- Admin. routes
- parenteral
- Indications
- psoriasis, immune system disease, Sjogren syndrome, rheumatoid arthritis
via ChEMBL · EBI
Wikidata facts
- Subclass of
- chemical compound
- Has use
- medication
Show 4 more facts
- World Health Organisation international non-proprietary name
- efalizumab
- defined daily dose
- 10
- has characteristic
- biopharmaceutical
- subject has role
- monoclonal antibody
via Wikidata · CC0
~1 min read
Encyclopedic overview
1 sectionsContents
- References
Efalizumab (brand name Raptiva) is a formerly available medication designed to treat autoimmune diseases, originally marketed to treat psoriasis. It is a recombinant humanized monoclonal antibody administered once weekly by subcutaneous injection. Efalizumab binds to the CD11a subunit of lymphocyte function-associated antigen 1 and acts as an immunosuppressant by inhibiting lymphocyte activation and cell migration out of blood vessels into tissues. Efalizumab was associated with fatal brain infections and was withdrawn from the market in 2009.
Known side effects include bacterial sepsis, viral meningitis, invasive fungal disease and progressive multifocal leukoencephalopathy (PML), a brain infection caused by reactivation of latent JC virus infection. Four cases of PML were reported in plaque psoriasis patients, an incidence of approximately one in 500 treated patients.
Excerpted from Wikipedia’s “efalizumab” article, available under the CC BY-SA 4.0 licence.